SSIINasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

SS Innovations International, Inc.

SS Innovations International, Inc. develops, manufactures, and sells the SSi Mantra surgical robotic system and related SSi Mudra instruments and accessories. The company is based in the United States but its manufacturing and commercial footprint is centered in India, with sales and support activities extending into selected international markets.

Liikevaihto42,5milj. USD
+105,7 %v/v
Liikevoitto (EBIT)−8,2milj. USD
+56,8 %v/v
EBIT-marginaali−19,3%
+72,6 %-yks.v/v
Nettotulos−12,1milj. USD
+36,7 %v/v
Vapaa kassavirta−22,2milj. USD
−118,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−40−200204060milj. USD202020212022: 1,4 milj. USD2022: EBIT −5,7 milj. USD20222023: 5,9 milj. USD2023: EBIT −20 milj. USD20232024: 21 milj. USD2024: EBIT −19 milj. USD20242025: 42 milj. USD2025: EBIT −8,2 milj. USD202542−8,2
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Surgical robotic systems90 %

The SSi Mantra robotic platform sold to hospitals and surgical centers.

Instruments and accessories7 %

Reusable and consumable instruments, accessories, and stocking orders for installed systems.

Warranty and service revenue2 %

Warranty coverage, readiness support, maintenance plans, and technical support services.

Lease and pay-per-procedure income1 %

Recurring income from systems placed under usage-based or deferred commercial models.

Tuotteet

Raportoitu · osuus liikevaihdosta
90,3%FY2025100 %
  • System Sales90,3 %
  • Instruments Sale7,5 %
  • Warranty Sale2,1 %
  • Lease Income0,2 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Customers are hospitals, surgical centers, and physicians that acquire robotic surgery systems for use in urology, general surgery, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac procedures. The company also serves customers that prefer usage-based or deferred payment structures, which lowers upfront adoption barriers for capital-constrained healthcare providers.

Hospitals and surgical centers

Buy SSi Mantra systems for operating room use across multiple specialties and to build robotic surgery programs.

Physicians and surgical teams

Use the platform and buy into training, proctoring, and support services to adopt robotic procedures.

Installed-base customers

Reorder instruments, accessories, warranty coverage, and maintenance services after system installation.

Usage-based customers

Adopt pay-per-procedure or deferred models to access the system with lower upfront capital needs.

Strategia

The company’s strategy is to expand access to surgical robotics by offering a lower-cost, next-generation system with flexible commercial models. It is also building recurring revenue through instruments, accessories, service plans, and usage-based arrangements while broadening regulatory approvals and market reach.

Expand installed base of SSi MantraKeskipitkä aikaväli

A larger installed base supports system sales, instrument pull-through, and service revenue.

Increase recurring revenue mixKeskipitkä aikaväli

Instruments, accessories, warranty, and service plans create repeat revenue after system placement.

Broaden product portfolioKeskipitkä aikaväli

New instruments and specialty applications increase the number of procedures the platform can support.

Expand regulatory and market accessPitkä aikaväli

Approvals are needed to sell in regulated markets and to scale beyond current geographies.

Maantiede

Q1/2026

Substantially all reported sales have been in India, with additional individual sales in the United Arab Emirates, Ecuador, Iraq, Nepal, Colombia, Indonesia, and the Philippines. Manufacturing operations are based in India, which also supports the company’s service network and distributor relationships.

Intia99 %
South America0,7 %
Philippines0,3 %
Indonesia0,2 %
United Arab Emirates0,1 %
NP0,1 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The business depends on continued adoption of a relatively new robotic platform, successful regulatory approvals, and the ability to finance growth. It also faces execution risk around manufacturing, service quality, and customer uptake of alternative payment models, along with the usual risks of a capital-intensive medical device company.

Järjestetty vakavuuden mukaan
Regulatory approval delays or denialsKorkea

Sales in regulated markets depend on obtaining and maintaining approvals for the robotic system and related devices.

Kohdistuu: International expansion

Financing and liquidity dependenceKorkea

The company has relied on debt and equity offerings and may need additional capital to fund operations and expansion.

Kohdistuu: Corporate funding

Geographic concentration in IndiaKorkea

Substantially all sales have been in India, so demand or policy changes there would affect results disproportionately.

Kohdistuu: India

Commercial adoption riskKeskitaso

Robotic surgery adoption depends on surgeon acceptance, hospital budgets, and willingness to switch from established systems.

Kohdistuu: System sales

Manufacturing and service execution riskKeskitaso

The model requires reliable production, installation, maintenance, and technical support to protect customer uptime.

Kohdistuu: India operations and distributor network

Kysy Clarifolta: SS Innovations International, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for mixed commercial models

Different sales structures recognize revenue at different times, affecting comparability across periods.

Vaikutus: System sales, lease income, and recurring service revenue

Standalone selling price allocation

Bundled contracts require allocation across systems, instruments, accessories, and services.

Vaikutus: Reported mix and timing of revenue

Stock-based compensation

Fair value estimates and vesting schedules can create large non-cash expenses and volatility.

Vaikutus: Operating expenses and net loss

Going-concern and financing assumptions

Financial statements assume continued access to capital even though funding is not committed.

Vaikutus: Liquidity disclosures and investor risk assessment

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

SS Innovations International, Inc. (SSII) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo